Hung T. Khong

4.8k total citations · 1 hit paper
71 papers, 3.0k citations indexed

About

Hung T. Khong is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Hung T. Khong has authored 71 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 25 papers in Immunology and 18 papers in Molecular Biology. Recurrent topics in Hung T. Khong's work include CAR-T cell therapy research (24 papers), Immunotherapy and Immune Responses (23 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Hung T. Khong is often cited by papers focused on CAR-T cell therapy research (24 papers), Immunotherapy and Immune Responses (23 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Hung T. Khong collaborates with scholars based in United States, Japan and China. Hung T. Khong's co-authors include Nicholas P. Restifo, Steven A. Rosenberg, Paul A. Antony, Christopher A. Klebanoff, Douglas C. Palmer, Qiong J. Wang, Paul F. Robbins, Ming Tan, Øystein Fodstad and Yangbing Zhao and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Hung T. Khong

65 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Natural selection of tumor variants in the generation of “tumor escape” phenotypes

2002 802 citations Hung T. Khong, Nicholas P. Restifo Nature Immunology profile →

Peers

Hung T. Khong

ONCOL

IMMUN

GENET

Matthew J. Cotter United States

Sandrine Valsesia‐Wittmann France

Pia Kvistborg Netherlands

Evelyn Ullrich Germany

Riccardo Mezzadra United States

Catherine Koebel United States

Michel DuPage United States

Todd D. Armstrong United States

Sofie Wilgenhof Belgium

Cristina Puig-Saus United States

Matthew J. Cotter United States

Hung T. Khong

1.0k ×0.5

ONCOL

1.8k ×1.1

IMMUN

807 ×0.8

387 ×0.9

GENET

394 ×1.2

Citations per year, relative to Hung T. Khong Hung T. Khong (= 1×) peers Matthew J. Cotter

Countries citing papers authored by Hung T. Khong

Since Specialization

Citations

This map shows the geographic impact of Hung T. Khong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hung T. Khong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hung T. Khong more than expected).

Fields of papers citing papers by Hung T. Khong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hung T. Khong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hung T. Khong. The network helps show where Hung T. Khong may publish in the future.

Co-authorship network of co-authors of Hung T. Khong

This figure shows the co-authorship network connecting the top 25 collaborators of Hung T. Khong. A scholar is included among the top collaborators of Hung T. Khong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hung T. Khong. Hung T. Khong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Soliman, Hatem, Hyo S. Han, Blaise Mooney, et al.. (2023). Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nature Medicine. 29(2). 450–457. 50 indexed citations

Han, Hyo S., Ricardo Costa, Susan Hoover, et al.. (2023). Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.. Journal of Clinical Oncology. 41(16_suppl). 596–596. 1 indexed citations

Kaklamani, Virginia, François‐Clément Bidard, Patrick Neven, et al.. (2023). Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).. Journal of Clinical Oncology. 41(16_suppl). 1070–1070. 4 indexed citations

Boulware, David, et al.. (2022). A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes. Breast Cancer Targets and Therapy. Volume 14. 199–210. 3 indexed citations

Sun, James, Junjie Ma, Weihong Sun, et al.. (2021). Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. Cancer Medicine. 10(21). 7665–7672. 13 indexed citations

West, Jeffrey, Mark Robertson‐Tessi, Kimberly A. Luddy, et al.. (2019). The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory. JCO Clinical Cancer Informatics. 3(3). 1–12. 18 indexed citations

Khong, Brian, et al.. (2018). Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2. BMC Cancer. 18(1). 1007–1007. 1 indexed citations

Andtbacka, Robert H.I., Merrick I. Ross, Sanjiv S. Agarwala, et al.. (2017). Subgroup analysis of a phase II multicenter trial of HF10, oncolytic virus immunotherapy, and ipilimumab combination treatment in unresectable or metastatic melanoma patients. Annals of Oncology. 28. x113–x113.

Werner, Theresa L., Abhijit Ray, John G. Lamb, et al.. (2017). A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clinical Breast Cancer. 17(7). 503–509. 6 indexed citations

10.

Andtbacka, Robert H.I., Merrick I. Ross, Sanjiv S. Agarwala, et al.. (2016). Tumor response from phase II study of combination treatment with intratumoral HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma. Annals of Oncology. 27. vi393–vi393. 3 indexed citations

11.

Liu, Zixing, Hao Liu, Shruti Desai, et al.. (2012). miR-125b Functions as a Key Mediator for Snail-induced Stem Cell Propagation and Chemoresistance. Journal of Biological Chemistry. 288(6). 4334–4345. 48 indexed citations

12.

Radfar, Soroosh, Yixiang Wang, & Hung T. Khong. (2007). “Chemocentric” chemoimmunotherapy: presensitization of tumor cells with activated CD4+ T cells synergistically enhances the cytotoxic effect of chemotherapy. Cancer Research. 67. 956–956. 1 indexed citations

13.

Riker, Adam I., et al.. (2007). Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opinion on Biological Therapy. 7(3). 345–358. 40 indexed citations

14.

Wang, Qiong J., Ken‐ichi Hanada, Donna Perry-Lalley, et al.. (2005). Generating Renal Cancer-Reactive T Cells Using Dendritic Cells (DCs) to Present Autologous Tumor. Journal of Immunotherapy. 28(6). 551–559. 10 indexed citations

15.

Liu, Gentao, Yasuharu Akasaki, Hung T. Khong, et al.. (2005). Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene. 24(33). 5226–5234. 64 indexed citations

16.

Klebanoff, Christopher A., Hung T. Khong, Paul A. Antony, Douglas C. Palmer, & Nicholas P. Restifo. (2004). Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends in Immunology. 26(2). 111–117. 346 indexed citations

17.

Khong, Hung T., James C. Yang, Suzanne L. Topalian, et al.. (2004). Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen. Journal of Immunotherapy. 27(6). 472–477. 48 indexed citations

18.

Khong, Hung T. & Steven A. Rosenberg. (2002). Pre-Existing Immunity to Tyrosinase-Related Protein (TRP)-2, a New TRP-2 Isoform, and the NY-ESO-1 Melanoma Antigen in a Patient with a Dramatic Response to Immunotherapy. The Journal of Immunology. 168(2). 951–956. 62 indexed citations

19.

Khong, Hung T., et al.. (2002). Identification of Endogenous HLA-A2–Restricted Reactivity Against Shared Melanoma Antigens in Patients Using the Quantitative Real-Time Polymerase Chain Reaction. Journal of Immunotherapy. 25(1). 63–71. 3 indexed citations

20.

Khong, Hung T. & Nicholas P. Restifo. (2002). Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nature Immunology. 3(11). 999–1005. 802 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact